COMPANION-002

tovecimig/CTX-009-002

Biliary Tract Cancer (BTC)

A Phase 2/3 study in adults with unresectable, advanced, metastatic or recurrent biliary tract cancer who have received one prior systemic chemotherapy regimen. This randomized study assesses the efficacy and safety of CTX-009 in combination with paclitaxel versus paclitaxel alone as a second-line therapy. The primary endpoint is Overall Response Rate (ORR) and the secondary endpoints include progression-free (PFS) survival and overall survival (OS). Study enrollment is now closed.

Participating Locations clinicaltrials.gov
video
Watch our presentation

Ver vídeo con subtítulos en español

观看带有西班牙语字幕的视频。

CTX-8371

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

clinicaltrials.gov

COMPANION-002 Trial Locations

Compass Therapeutics is committed to conducting rigorous and ethical research. Our clinical studies, and the associated protocols, are approved by the appropriate ethics committee or institutional review board at each participating center. Our clinical study protocol and procedures are established to ensure compliance with any applicable governmental regulations, ethical guidelines, and institutional requirements, including the Declaration of Helsinki, the US FDA, and applicable institutional bylaws.